Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice

被引:0
作者
Mahmood, Iftekhar [1 ]
机构
[1] Mahmood Clin Pharmacol Consultancy LLC, 1709 Piccard DR, Rockville, MD 20850 USA
关键词
PARAMETERS; SELECTION; HUMANS;
D O I
10.1007/s13318-024-00918-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectiveCurrently, there is no available method for the prediction of first-in-human (FIH) dose for chimeric antigen receptor-T (CAR-T) cells. The objective of this work was to predict the FIH dose of CAR-T cells from different doses given to mice.MethodsIn this study, six scaling methods were evaluated for the prediction of FIH dose for CAR-T cells. The methods were body weight-based fixed exponents such as 1.0 and 0.75, human equivalent dose (HED) using exponents 0.33, two modified HED methods such as using total animal dose (in place of per kg basis) and body surface area in place of body weight using total animal dose with exponent 0.33 and a physiological factor derived from physiological parameters. The FIH doses of six CAR-T cells were predicted in this study. The predicted human doses were compared with the recommended human dose by the US-FDA for four CAR-T cell products, and the literature data were used for the remaining two CAR-T cells.ResultsThe results indicated that the two modified HED methods and physiological factor are the best and reliable methods for the prediction of FIH dose for CAR-T cells.ConclusionsThe proposed methods are simple and accurate in their predictive power and can be used on a spreadsheet.
引用
收藏
页码:715 / 722
页数:8
相关论文
共 27 条
[1]   Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany [J].
Albinger, Nawid ;
Hartmann, Jessica ;
Ullrich, Evelyn .
GENE THERAPY, 2021, 28 (09) :513-527
[2]  
[Anonymous], 2018, EMA4855632018 CHMP
[3]  
[Anonymous], 2015, CONSIDERATIONS DESIG
[4]   FIRST-TIME-IN-HUMAN DOSE SELECTION - ALLOMETRIC THOUGHTS AND PERSPECTIVES [J].
BOXENBAUM, H ;
DILEA, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10) :957-966
[5]   INTERSPECIES PHARMACOKINETIC SCALING AND THE EVOLUTIONARY-COMPARATIVE PARADIGM [J].
BOXENBAUM, H .
DRUG METABOLISM REVIEWS, 1984, 15 (5-6) :1071-1121
[6]   How first-time-in-human studies are being performed: A survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004 [J].
Buoen, C ;
Bjerrum, OJ ;
Thomsen, MS .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (10) :1123-1136
[7]  
Chappell WR., 1991, ADV DRUG RES, P1, DOI 10.1016/B978-0-12-013320-8.50005-8
[8]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[9]   Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application [J].
Erdogan, Ebru ;
Yalcin, Koray ;
Hemsinlioglu, Cansu ;
Sezgin, Aslihan ;
Seyis, Utku ;
Kancagi, Derya Dilek ;
Tastan, Cihan ;
Yurtsever, Bulut ;
Turan, Raife Dilek ;
Cakirsoy, Didem ;
Abanuz, Selen ;
Karakus, Gozde Sir ;
Elek, Muhammer ;
Bekoz, Huseyin Saffet ;
Gemici, Ali Ihsan ;
Sargin, Deniz ;
Arat, Mutlu ;
Ferhanoglu, Burhan ;
Pekguc, Ebru ;
Ornek, Serdar ;
Buyuktas, Deram ;
Birgen, Nur ;
Ratip, Siret ;
Ovali, Ercument .
TURKISH JOURNAL OF HEMATOLOGY, 2022, 39 (03) :206-210
[10]  
FDA Package Insert, 2022, CARVYKTI CILTACABTAG